A5101652052- Toxin Mechanisms and Immunotoxins
- Veterinary medicine and infectious diseases
- Pharmacological Effects of Natural Compounds
- Macrophage Migration Inhibitory Factor
- Bacterial Identification and Susceptibility Testing
- Antimicrobial Resistance in Staphylococcus
- Seaweed-derived Bioactive Compounds
- Antibiotics Pharmacokinetics and Efficacy
- Immune Response and Inflammation
Charles River Laboratories (United Kingdom)
2020-2024
Fucoidans are known to be effective inhibitors of inflammation, and virus binding cellular entry.
Lefamulin is a first-in-class systemic pleuromutilin antimicrobial and potent inhibitor of bacterial translation, the most recent novel approved for treatment community-acquired pneumonia (CAP). It exhibits antibacterial activity against prevalent pathogens that cause typical atypical other infectious diseases. Early studies indicate additional anti-inflammatory activity. In this study, we further investigated immune-modulatory lefamulin in influenza A/H1N1 acute respiratory distress...
Abstract Background Lefamulin (LEF) is a pleuromutilin antibiotic approved by the United States (US) FDA for treatment of community-acquired bacterial pneumonia in adults. In addition to potent antibacterial activity, LEF has demonstrated anti-inflammatory activity an LPS induced lung neutrophilia model mice. We investigated lefamulin H1N1 influenza mouse comparison oseltamivir (OTV) and azithromycin (AZM). Methods Infection was performed BALB/c mice intranasal challenge ∼70 pfu virus...
Introduction. Ceftobiprole is an advanced-generation broad-spectrum parenteral cephalosporin with activity against MSSA and MRSA. Gap Statement. not currently approved for use to treat S. aureus bacteremia phase three clinical trials are taking place. Drug approval requires further pre-clinical evidence support this new indication. Aim. The aim of study was evaluate the efficacy ceftobiprole at human equivalent efficacious exposure (considering a 500 mg q8h dosing regimen infused over 2 h)...